公开(公告)号：US20220331303A1

公开(公告)日：2022-10-20

申请号：US17642337

申请日：2020-09-12

申请人： Takeda Pharmaceutical Company Limited

发明人： Deborah HARTMAN ,  Rebecca EVANS ,  Helene FAESSEL ,  Robert RUBENS ,  Shinichiro TANAKA

IPC分类号： A61K31/445 ,  A61P25/26 ,  A61K45/06

摘要： Described herein are methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)-piperidine-1-carboxylate (Compound (I)), compositions comprising Compound (I), and the use of Compound (I) for the treatment of excessive sleepiness in a subject in need thereof.

公开(公告)号：US20220339143A1

公开(公告)日：2022-10-27

申请号：US17642331

申请日：2020-09-12

申请人： Takeda Pharmaceutical Company Limited

发明人： Deborah HARTMAN ,  Rebecca EVANS ,  Helene FAESSEL ,  Shinichiro TANAKA

IPC分类号： A61K31/445 ,  A61P25/26 ,  A61K9/00

摘要： A method for treating narcolepsy type 1 in a subject in need thereof is disclosed, comprising administering to the subject an effective amount of methyl 3-((methylsulfonyl)anhino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate (Compound (I)), or a salt thereof, wherein plasma concentration for Compound (I) is about 5.04 ng/mL or more for about 1 hour or more. Compositions for treating narcolepsy type 1 comprising Compound (I) are also disclosed.